COST-EFFECTIVENESS OF SYSTEMIC TREATMENT INTENSIFICATION IN MEN WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

被引：0
|
作者：
Sathianathen, Niranjan
Lawrentschuk, Nathan
Azad, Arun
Konety, Badrinath
Murphy, Declan
机构：
来源：
JOURNAL OF UROLOGY | 2023年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD16-08
引用
收藏
页码：E492 / E492
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Nidhi Gupta
    Dharna Gupta
    Kiran Gopal Vaska
    Shankar Prinja
    Applied Health Economics and Health Policy, 2024, 22 : 415 - 426
  • [2] Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India
    Gupta, Nidhi
    Gupta, Dharna
    Vaska, Kiran Gopal
    Prinja, Shankar
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2024, 22 (03) : 415 - 426
  • [3] Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen, Niranjan J.
    Lawrentschuk, Nathan
    Konety, Badrinath
    Azad, Arun A.
    Corcoran, Niall M.
    Bolton, Damien M.
    Murphy, Declan G.
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (04): : 870 - 876
  • [4] A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
    Sung, W. W.
    Choi, H. C.
    Luk, P. H.
    So, T. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S1326 - S1326
  • [5] A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer
    Sung, Winnie W. Y.
    Choi, Horace C. W.
    Luk, Peter H. Y.
    So, Tsz Him
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [6] A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer
    Sathianathen, Niranjan J.
    Alarid-Escudero, Fernando
    Kuntz, Karen M.
    Lawrentschuk, Nathan
    Bolton, Damien M.
    Murphy, Declan G.
    Kim, Simon P.
    Konety, Badrinath R.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 649 - 655
  • [7] Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
    Ding, Haiying
    Li, Shujing
    Xu, Xinglu
    Xu, Weiben
    He, Chaoneng
    Xin, Wenxiu
    Zhan, ZhaJun
    Fang, Luo
    BMJ OPEN, 2024, 14 (07): : 1 - 6
  • [8] Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer
    Wala, Jeremiah
    Nguyen, Paul
    Pomerantz, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (20) : 3584 - +
  • [9] Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer
    Beca, Jaclyn
    Majeed, Habeeb
    Chan, Kelvin K. W.
    Hotte, Sebastian J.
    Loblaw, Andrew
    Hoch, Jeffrey S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2019, 13 (12): : 396 - 403
  • [10] Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
12345